Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889792 | 0.88 | NPC1 (0.61) | NPC1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL7864711 | 0.88 | NPC1 (0.61) | NPC1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL27810867 | 0.87 | ALDH1A1 (0.72) | NPC1ALDH1A1LMNASMN1; SMN2NR1H4 | |
| SCHEMBL3889316 | 0.87 | ALDH1A1 (0.59) | NPC1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL7869047 | 0.87 | ALDH1A1 (0.59) | NPC1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL13907808 | 0.86 | ALDH1A1 (0.58) | NPC1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL13229362 | 0.86 | NPC1 (0.59) | NPC1ALDH1A1LMNAKMT2ANR1H4 | |
| SCHEMBL13042147 | 0.82 | KMT2A (0.60) | NPC1ALDH1A1LMNAKMT2ANR1H4 | |
| SCHEMBL13229283 | 0.81 | NPC1 (0.59) | NPC1ALDH1A1LMNAKMT2ANR1H4 | |
| SCHEMBL13325935 | 0.81 | NPC1 (0.59) | NPC1ALDH1A1LMNAKMT2ANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7713961-B2 | Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7713961-B2 | Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | PSEN1, PSEN2, BACE1 | NPC1 1245/4885ALDH1A1 511/4885LMNA 75/4885 |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | PSEN1, PSEN2, BACE1 | NPC1 1245/4885ALDH1A1 511/4885LMNA 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.